Dihexa

Last updated: September 1, 2026. This page was originally published as a placeholder on April 24 and has been expanded with research and regulatory context. It reflects the outcome of the July 23-24 PCAC meeting and the clinical record of Dihexa’s closest derivative; the FDA’s final 503A Bulks List decision remains pending.

Quick Summary

• What it is: Dihexa (also known as N-hexanoic-Tyr-Ile-Ahx-His(3-CH₂NH-cyclo(5-F₆-C₀₁)) amide) is a synthetic angiotensin IV analog developed for cognitive enhancement.
• Regulatory status: One of 12 therapeutic peptides reclassified by the FDA on April 15, 2026. Removed from Category 2 (significant safety concerns) into Category 1 (enforcement discretion). Dihexa was not on the July 23-24 PCAC agenda, and its Category 1 placement remains in force while the FDA finalizes the 503A Bulks List.
• Key research area: Preclinical studies suggest activity at the hepatocyte growth factor (HGF) receptor c-Met, with potential applications in synaptic plasticity and cognitive function.
• Human data: Very limited. No large peer-reviewed human trials of Dihexa itself have been published; the closest clinical read-through is fosgonimeton (ATH-1017), a small-molecule derivative that failed a Phase 2/3 Alzheimer’s trial in 2024.

What Is Dihexa?

Dihexa is a synthetic peptide first described in the scientific literature by researchers studying angiotensin IV (AngIV) analogs. Unlike most therapeutic peptides discussed in the compounding policy context — which are typically derived from naturally occurring signaling molecules — Dihexa is a wholly synthetic construct designed to improve upon the pharmacokinetic properties of earlier AngIV-derived compounds.

The peptide was originally developed by researchers investigating the renin-angiotensin system’s role in cognitive function. Early AngIV analogs showed promise in animal models of memory and learning but suffered from poor metabolic stability. Dihexa was designed with structural modifications — including a hexanoic acid tail and a reduced peptide bond — intended to improve its resistance to enzymatic degradation and blood-brain barrier penetration.

Research Status

Preclinical Evidence

The majority of published research on Dihexa comes from the laboratory of Dr. Joseph W. Harding and colleagues at Washington State University, who hold several patents related to the compound. Key findings from this body of work include:

• Memory enhancement: Animal studies have reported that Dihexa administration improves performance in the Morris water maze and other spatial learning tasks, and partially restores cognitive performance in scopolamine-treated rodent models of memory impairment.
• Synaptic plasticity: The compound has been shown to increase dendritic spine density in hippocampal neurons in vitro, suggesting a potential mechanism for its reported cognitive effects.
• Potency: The original preclinical work reported synaptogenic activity at picomolar concentrations, an unusually high potency that has made Dihexa a recurring reference point in discussions of HGF/c-Met-targeted cognitive compounds.
• c-Met receptor activity: Dihexa is believed to act as a positive modulator of the hepatocyte growth factor (HGF) receptor c-Met, a signaling pathway involved in neuronal survival and synaptic function.

The mechanism is summarized in a 2015 review by Wright and Harding, “The Brain Hepatocyte Growth Factor/c-Met Receptor System: A New Target for the Treatment of Alzheimer’s Disease” (Journal of Alzheimer’s Disease, 45(4):985–1000), which frames the HGF/c-Met system as an under-explored therapeutic target for slowing neurodegeneration. It is this same HGF/c-Met hypothesis — rather than Dihexa itself — that has been carried into human testing.

Human Clinical Data

Published human data on Dihexa is extremely limited. As of May 2026, no large-scale, peer-reviewed clinical trials examining Dihexa’s safety or efficacy in humans have been published in indexed medical journals. This places Dihexa among the least clinically characterized of the 12 peptides reclassified by the FDA on April 15.

The gap between preclinical promise and clinical evidence is particularly wide for Dihexa compared to compounds like BPC-157 or GHK-Cu, which have more substantial human safety records. This lack of human data is a significant consideration for regulatory decision-making and for clinicians evaluating whether to prescribe the compound.

Clinical Translation: The Fosgonimeton Read-Through

The most direct test of Dihexa’s HGF/c-Met hypothesis in humans came not from Dihexa itself but from a chemically related derivative. Fosgonimeton (ATH-1017), a small-molecule prodrug developed from Dihexa’s chemistry by Athira Pharma (since renamed Quince Therapeutics), targets the same HGF/c-Met pathway and was advanced into clinical trials for Alzheimer’s disease and Parkinson’s disease.

The outcome was discouraging for the hypothesis. A Phase 1 study (NCT03298672) reported that fosgonimeton was safe and well tolerated in Alzheimer’s patients, but the subsequent Phase 2/3 LIFT-AD trial failed in September 2024, showing no benefit over placebo on its primary cognitive endpoint in mild-to-moderate Alzheimer’s disease.

That failure does not settle the question of Dihexa — fosgonimeton is a distinct molecule, and Dihexa itself has not been through equivalent human testing — but it is the closest clinical data point available, and it leans negative for the broader HGF/c-Met cognitive strategy. For readers and clinicians evaluating Dihexa, the fosgonimeton record is the most important piece of recent context: the pathway Dihexa is built around has been tested in humans and, so far, has not cleared the bar.

Regulatory Status

April 15, 2026 Reclassification

The FDA’s April 15, 2026 action removed Dihexa from the 503A “demonstrably difficult to compound” list (previously Category 2) and placed it into Category 1 (enforcement discretion). This action cleared the legal compounding path for the compound under valid prescriptions through licensed 503A pharmacies.

Important distinction: Unlike GHK-Cu, which was listed in Category 1 from the start of the April 15 action, Dihexa was initially among the 12 peptides targeted for reclassification. Its current Category 1 placement means the FDA will exercise enforcement discretion regarding its compounding, but the agency has not made a final determination about its placement on the 503A Bulks List.

Post-PCAC Status

The Pharmacy Compounding Advisory Committee met July 23-24, 2026, and recommended six of the seven Category 2 peptides on its agenda — BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon — for inclusion on the 503A Bulks List, despite reservations from the agency’s own reviewers. DSIP was the only agenda peptide not recommended. The vote is a recommendation to the FDA, not a final agency decision; the FDA has not yet published a final 503A Bulks List ruling.

Dihexa was not on the July agenda. Its Category 1 (enforcement discretion) placement, established by the April 15 reclassification, is unchanged by the PCAC vote. Dihexa’s Category 1 status suggests a lower regulatory risk profile than the Category 2 compounds, but its final bulks-list placement remains formally outstanding until the FDA acts.

What This Means for Prescribers and Patients

For clinicians and patients considering Dihexa, the regulatory landscape has improved substantially since the April 15 reclassification, but significant uncertainties remain:

1. Legal access: Licensed prescribers can now prescribe Dihexa through PCAB-accredited compounding pharmacies under valid patient prescriptions, subject to state pharmacy board rules.
2. Evidence gap: The limited human safety data means that prescribing decisions should be made with careful informed consent.
3. Regulatory uncertainty: The July PCAC meeting did not address Dihexa, and its Category 1 status stands. The FDA’s final 503A Bulks List decision — still pending after the committee’s July recommendation — could ultimately affect prescribing and compounding access.

Standard clinical precautions apply: work with a licensed prescriber qualified to evaluate whether the compound is appropriate; source through accredited compounding pharmacies, not the research-chemical channel; and verify state-specific pharmacy board rules.

Future Outlook

PeptidesBeat will update this guide as new research emerges and as the FDA finalizes the 503A Bulks List following the July PCAC recommendation. Dihexa remains among the least clinically characterized of the 12 reclassified peptides, and any peer-reviewed human data would meaningfully change the evidence picture.

The clearest near-term signal will come from the broader HGF/c-Met field rather than from Dihexa directly. If a successor program to fosgonimeton re-tests the hypothesis and clears a Phase 3 bar, that would materially change how Dihexa’s mechanism — and by extension Dihexa itself — is viewed. Until then, the compound sits in an unusual position: a Category 1 regulatory status with a preclinical rationale that its closest clinical relative has so far failed to validate.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.